Patents by Inventor Umesh CHAUDHARI
Umesh CHAUDHARI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220315669Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy.Type: ApplicationFiled: March 14, 2022Publication date: October 6, 2022Inventors: Marie Baccara-Dinet, Corinne Hanotin, Laurence Bessac, Umesh Chaudhari, Robert C. Pordy, William J. Sasiela, Daniel A. Schwemmer Gipe
-
Publication number: 20220218823Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used.Type: ApplicationFiled: December 23, 2021Publication date: July 14, 2022Inventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari
-
Patent number: 11306155Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy.Type: GrantFiled: December 9, 2019Date of Patent: April 19, 2022Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.Inventors: Marie Baccara-Dinet, Corinne Hanotin, Laurence Bessac, Umesh Chaudhari, Robert C. Pordy, William J. Sasiela, Daniel A. Schwemmer Gipe
-
Patent number: 11246925Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used.Type: GrantFiled: March 26, 2019Date of Patent: February 15, 2022Assignee: SANOFI BIOTECHNOLOGYInventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari
-
Publication number: 20200255544Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and established CHD or CHD risk equivalents that are not adequately controlled by maximum tolerated dose statin therapy.Type: ApplicationFiled: October 24, 2019Publication date: August 13, 2020Inventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari, Robert Pordy, Daniel A. Schwemmer Gipe
-
Publication number: 20200216565Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy.Type: ApplicationFiled: December 9, 2019Publication date: July 9, 2020Inventors: Marie Baccara-Dinet, Corinne Hanotin, Laurence Bessac, Umesh Chaudhari, Robert C. Pordy, William J. Sasiela, Daniel A. Schwemmer Gipe
-
Patent number: 10544232Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy.Type: GrantFiled: July 16, 2015Date of Patent: January 28, 2020Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.Inventors: Marie Baccara-Dinet, Corinne Hanotin, Laurence Bessac, Umesh Chaudhari, Robert C. Pordy, William J. Sasiela, Daniel A. Schwemmer Gipe
-
Publication number: 20190343719Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used.Type: ApplicationFiled: March 26, 2019Publication date: November 14, 2019Inventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari
-
Publication number: 20170340515Abstract: The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact.Type: ApplicationFiled: May 15, 2017Publication date: November 30, 2017Inventors: Corinne HANOTIN, Laurence BESSAC, Umesh CHAUDHARI
-
Publication number: 20170266079Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used.Type: ApplicationFiled: December 22, 2016Publication date: September 21, 2017Inventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari
-
Patent number: 9682013Abstract: The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact.Type: GrantFiled: January 27, 2012Date of Patent: June 20, 2017Assignee: SANOFI BIOTECHNOLOGYInventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari
-
Patent number: 9561155Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used.Type: GrantFiled: January 27, 2012Date of Patent: February 7, 2017Assignee: SANOFI BIOTECHNOLOGYInventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari
-
Publication number: 20160137745Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy.Type: ApplicationFiled: July 16, 2015Publication date: May 19, 2016Inventors: Marie Baccara-Dinet, Corinne Hanotin, Laurence Bessac, Umesh Chaudhari, Robert C. Pordy, William J. Sasiela, Daniel A. Schwemmer Gipe
-
Publication number: 20160137746Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and established CHD or CHD risk equivalents that are not adequately controlled by maximum tolerated dose statin therapy.Type: ApplicationFiled: July 16, 2015Publication date: May 19, 2016Inventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari, Robert Pordy, Daniel A. Schwemmer Gipe
-
Publication number: 20150140002Abstract: The present invention provides methods for treating hyperlipidemia in patients who are not on statin therapy. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.Type: ApplicationFiled: October 10, 2014Publication date: May 21, 2015Inventors: Marie Baccara-Dinet, Laurence Bessac, Umesh Chaudhari, Corinne Hanotin, Robert C. Pordy, William J. Sasiela, Daniel A. Schwemmer Gipe
-
Publication number: 20140178402Abstract: The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact.Type: ApplicationFiled: January 27, 2012Publication date: June 26, 2014Applicant: SANOFIInventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari
-
Publication number: 20140154262Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used.Type: ApplicationFiled: January 27, 2012Publication date: June 5, 2014Applicant: SANOFIInventors: Corinne Hanotin, Laurence Bessac, Umesh Chaudhari
-
Publication number: 20120322759Abstract: The invention relates to an ultra-low molecular weight heparin with an average molecular weight of 2000 to 3000 Daltons, an anti-FXa activity of about 160 U/mg and an anti-FIIa activity of about 2 U/mg, in particular semuloparin, for use as an antithrombotic agent for the prophylaxis of venous thromboembolism in cancer patients receiving chemotherapy for locally advanced or metastatic solid tumors, more specifically in patients receiving chemotherapy for locally advanced or metastatic pancreatic or lung cancer, or for locally advanced or metastatic solid tumors with a VTE risk score equal to or greater than 3.Type: ApplicationFiled: May 11, 2012Publication date: December 20, 2012Applicant: AVENTIS PHARMA SAInventors: Umesh CHAUDHARI, Dominique DESTREE, Francesca LAWSON, Guillaume LECORPS